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clude that knockdown of hda-1 levels with 
RNA interference (RNAi) in skn-1 mutants 
leads to upregulation of end-1 transcripts 
and a decrease in its variability. Indeed, 
the coefficient of variation for end-1 levels 
does decrease with RNAi knockdown of 
hda-1 in skn-1 mutants as compared to the 
variation in skn-1 mutants alone. However, 
this is still markedly higher than the varia-
tion observed in the wild-type. It appears 
that the double-mutant phenotype is 
complex. Not only is end-1 derepressed, 
but the variation is also partially limited. Is 
the partial decrease in variation simply a 
byproduct of derepression of this gene? 
Or do multiple mechanisms feed into the 
control of variation? Or both? These ques-
tions are complex, but this paper lays the 
groundwork for addressing them.
The work of Raj and colleagues begins 
to address the mechanisms that cause 
incomplete penetrance. Their highly 
quantitative single molecule approach is 
new to developmental biology, which typ-
ically makes use of reporter transgenes, 
antibody staining, and in situ hybridiza-
tion to assess gene expression. With this 
methodology, Raj et al. clearly show that 
variation in expression occurs in specific 
mutant conditions and that the architec-
ture of a developmental network is able to 
compensate for noisy expression. How-
ever, one of the most challenging prob-
lems in the field of gene expression (in 
wild-type or mutant conditions) is to iden-
tify the source of transcriptional stochas-
ticity. Although a role for chromatin state 
is proposed in this paper, this is hardly 
surprising given that its regulation is so 
fundamental to gene expression in gen-
eral. The next challenge will be to show 
how these alterations affect variability in 
gene expression at individual loci.
Robustness compensates for varia-
tion caused by the stochastic low level 
expression of key regulators. However, 
mechanisms that ensure robustness also 
provide a buffer in the wild-type, which 
allows for the evolution of new regulatory 
interactions (for a review, see Masel and 
Siegal, 2009). It will be exciting to deter-
mine not only how variation occurs due 
to the break down of wild-type biologi-
cal programs but also how novel cryptic 
modes of regulation are revealed when 
robustness mechanisms are impaired. 
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MicroRNAs interact with Argonaute proteins to guide posttranscriptional gene silencing. Eiring et 
al. (2010) now show that miR-328 has a second function, acting as a decoy by binding to hnRNP 
E2 and lifting its translational repression of an mRNA involved in myeloid cell differentiation.Although microRNAs (miRNAs) were 
discovered a decade ago, a detailed 
understanding of these tiny gene regu-
lators is still in its infancy. Genes encod-
ing miRNAs are transcribed as primary 
miRNA transcripts (pri-miRNAs) by 
RNA polymerase II. Pri-miRNAs are 
processed by Drosha to produce stem-
loop-structured miRNA precursors (pre-
miRNAs). Pre-miRNAs are exported to 612 Cell 140, March 5, 2010 ©2010 Elsevierthe cytoplasm, where Dicer generates 
?21 nucleotide double-stranded RNA 
intermediates. Such double-stranded 
RNAs are processed further, and one 
strand, the mature miRNA, interacts 
with Argonaute (Ago) proteins to form 
miRNA-protein complexes (miRNPs) 
(Bartel, 2009; Carthew and Sontheimer, 
2009). miRNAs are able to silence 
gene expression posttranscriptionally  Inc.by binding to partially complemen-
tary target sites in the 3′ untranslated 
region (UTR) of target messenger RNAs 
(mRNAs), leading to repression of trans-
lation or destabilization of the mRNA by 
deadenylation. Almost perfectly com-
plementary target sites in the mRNA can 
be cleaved by the miRNA through an 
RNA interference-like mechanism (Fili-
powicz et al., 2008). In contrast to these 
inhibitory effects on gene expression, 
miRNAs can also stimulate the expres-
sion of target genes (Ørom et al., 2008; 
Vasudevan et al., 2007). In this issue, 
Eiring et al. (2010) report a new function 
for the human miRNA, miR-328. They 
show that miR-328 can act as a decoy 
by binding to a regulatory RNA binding 
protein and preventing it from blocking 
translation of mRNAs. Thus, miR-328 
has a dual role in the regulation of gene 
expression.
The RNA binding protein hnRNP E2, 
also called poly(rC) binding protein, 
interacts with a conserved C-rich bind-
ing site in the 5′ UTR of the C/EBPα 
mRNA and inhibits its translation (Figure 
1A). C/EBPα mRNA encodes a transcrip-
tion factor that is important for the differ-
entiation of myeloid progenitor cells into 
white blood cells called granulocytes in 
the bone marrow. The activity of hnRNP 
E2 is induced by the kinase activity of 
BCR/ABL, a fusion protein derived from 
the reciprocal translocation of chro-
mosomes 9 and 22. This chromosomal 
abnormality (called the Philadelphia chro-
mosome) and the BCR-ABL oncoprotein 
it encodes are present in about 95% of 
all patients with chronic myeloid leuke-
mia (CML). BCR/ABL prevents granu-
locytic differentiation, and thus allows 
myeloid progenitor cells to proliferate. 
The authors analyzed miRNA expression 
profiles in myeloid progenitor cells from 
CML patients in blast crisis that strongly 
express the BCR/ABL oncoprotein and 
found reduced expression of miR-328. 
They realized that the sequence of 
miR-328 is very similar to the hnRNP E2 
binding sequence found in the C/EBPα 
mRNA and hypothesized that the mature 
miR-328 might bind to hnRNP E2. Using 
several experimental approaches, they 
demonstrate that miR-328 interacts with 
hnRNP E2 under physiological condi-
tions and that surprisingly this interac-
tion is independent of Ago proteins and 
other proteins associated with the gene 
silencing machinery.
The C/EBPα protein drives myeloid cell 
differentiation, and hnRNP E2 inhibits 
this differentiation by blocking the trans-
lation of C/EBPα mRNA. Consequently, 
the authors surmised that ectopic 
expression of miR-328 should influence 
myeloid differentiation. Using a number 
of in vitro and in vivo assays, they dem-onstrate that miR-328 is able to lift trans-
lational inhibition of C/EBPα mRNA and 
drive CML blast cells to differentiate into 
granulocytes. The ability of miR-328 to 
rescue the differentiation of CML blast 
cells is due to its interaction with hnRNP 
E2 leading to the sequestration of hnRNP 
E2 and the restoration of C/EBPα mRNA 
figure 1. Regulation of hnRNP E2 by 
miR-328
(A) Myeloid progenitor cells from chronic myeloid 
leukemia (CML) patients express the fusion pro-
tein BCR/ABL kinase. In these cells, BCR-ABL ac-
tivates the RNA binding protein hnRNP E2, which 
interacts with the 5′ UTR of the C/EBPα mRNA 
leading to inhibition of its translation. C/EBPα is 
a transcription factor that drives the differentiation 
of myeloid progenitor cells into granulocytes in the 
bone marrow. Reduced C/EBPα protein levels in 
leukemic blast cells blocks their differentiation into 
granulocytes.
(B) The sequence of mature miR-328 is similar to 
the hnRNP E2 binding site in C/EBPα mRNA, en-
abling this miRNA to interact directly with hnRNP 
E2. The binding of miR-328 to hnRNP E2 releases 
C/EBPα mRNA from translational repression, res-
cuing C/EBPα protein production and resulting in 
differentiation of blast cells into granulocytes. In 
addition, C/EBPα stimulates miR-328 transcrip-
tion, thus forming a positive feedback loop that 
fine tunes the regulation of myeloid differentiation.Cell translation. Furthermore, the authors 
identified a positive regulatory feedback 
loop, which highlights the complexity of 
miRNA regulatory networks. They show 
not only that miR-328 regulates C/EBPα 
expression, but also that the C/EBPα 
protein induces miR-328 expression by 
binding directly to the miR-328 promoter 
(Figure 1B).
Is miR-328 a typical miRNA, or does it 
just act as a decoy for hnRNP E2? Search-
ing for targets using common miRNA 
target prediction algorithms, Eiring and 
colleagues validated the oncogene PIM1 
as a direct target of miR-328. PIM1 is a 
regulator of the cell cycle and apoptosis 
and is therefore important for the survival 
of leukemic blast cells expressing BCR/
ABL. Therefore, miR-328 has a dual func-
tion: on the one hand, it guides silencing 
of target genes, and on the other, it acts 
as a decoy blocking translational inhibi-
tion mediated by hnRNP E2.
It is well established that RNA bind-
ing proteins can modulate the function 
of miRNAs in different systems. For 
example, proteins like Deadend 1 or HuR 
(Hu antigen R, also known as ELAV1) 
can compete with miRNA binding sites 
on mRNAs and modulate miRNA func-
tion (Bhattacharyya et al., 2006; Kedde 
et al., 2007). The Eiring et al. findings are 
intriguing because an miRNA-mediated 
regulatory function associated with RNA 
binding proteins has not been reported 
before. Moreover, the general view of 
miRNA functions entails a model in 
which miRNAs serve as guides for Ago 
protein complexes, the actual mediators 
of posttranscriptional gene silencing. 
Eiring and coworkers show that miR-328 
can act independently of Ago proteins by 
interacting directly with hnRNP E2.
The discovery of this new function 
for miRNAs raises a number of fas-
cinating questions. How many other 
miRNAs are similar to the binding 
sequences of RNA binding proteins? 
What is the impact of miRNAs acting as 
decoys in the pathogenesis of cancer 
and other diseases? How are miRNAs 
released from Ago proteins and how 
is the interplay between the two path-
ways regulated? Future studies will be 
necessary to unravel the mechanistic 
details underlying the diverse functions 
of miRNAs both in healthy as well as 
diseased tissue.140, March 5, 2010 ©2010 Elsevier Inc. 613
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